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Abstract
S100B is a protein with dose-dependent neurotrophic and neurotoxic effects. Whether
S100B in psychotic disorder mirrors pathophysiological mechanisms (which elicit exacerba-
tion of disease) or compensatory action is unclear, as is its validity as a proxy marker for
brain status. Insight may be gained by examining associations between serum S100B and
indices of grey (cortical thickness (CT)) and white matter (fractional anisotropy (FA)), in rela-
tion to the absence or presence of (increased risk of) psychotic disorder. Blood samples and
cerebral magnetic resonance imaging (MRI) scans were acquired in 32 patients with psy-
chotic disorder, 44 non-psychotic siblings of patients with psychotic disorder and 26 con-
trols. Interactions between S100B and group were examined in separate models of CT and
FA measures with multilevel regression analyses weighted for number of vertices and vox-
els (i.e. units of volume) respectively. All analyses were adjusted for sex, age, body mass
index (BMI), scan sequence, handedness and highest level of education. Neither CT nor FA
was associated with S100B. There were no significant S100B × group interactions (CT: χ2 =
0.044, p = 0.978; FA: χ2 = 3.672, p = 0.159). No evidence was present for S100B as a proxy
marker of grey or white matter status. The association between S100B and brain measures
was not moderated by psychosis risk.
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Introduction
S100B is a protein with dose-dependent neurotrophic and neurotoxic effects. Previously, we
investigated serum protein S100B as a marker of familial risk of psychotic disorder. We did
not find S100B elevation in unaffected siblings of patients with psychotic disorder. Nor was
S100B elevated in patients with psychotic disorder in our samples (including patients generally
not in an acute stage of the disorder, with a mean illness duration <10 years) [1]. The absence
of S100B elevation in patients and siblings in our study, in combination with the previously
reported positive findings in predominantly hospitalized patients (with more severe psychopa-
thology), suggests that S100B elevations may reflect non-remitted illness processes in certain
patient populations. A systematic review and meta-analysis [2], which included our study,
showed a significant increase in S100B in patients with schizophrenia which remained present
after subgroup analyses to account for clinical and methodological heterogeneity (although
heterogeneity remained high in the subgroup analyses). Whether S100B in psychotic disorder
mirrors pathophysiological mechanisms (which elicit exacerbation of disease) or compensa-
tory action is unclear.
Aleksovska and colleagues [2] suggest that S100B is a candidate biomarker of neuroplastic-
ity although there is little literature to illustrate this. One study associated S100B overexpres-
sion in transgenic mice with neurogenesis in the hippocampus in stressful conditions [3]. In
other animal studies, posttraumatic intraventricular infusion of S100B has been shown to ben-
efit hippocampal neurogenesis and cognitive function [4, 5]. Human studies are at an earlier
stage. Streitbu¨rger and colleagues [6] were the first to test the validity of S100B as a peripheral
marker for the human brain. Their study demonstrated that S100B was negatively correlated
with fractional anisotropy (FA) and positively correlated with radial diffusivity in healthy
females, possibly signaling diminished fiber directionality and demyelination. No associations
between S100B and grey matter indices were found.
The current study may be considered a replication study of Streitbu¨rger’s work [6], con-
firming or refuting their finding of S100B as a biomarker for the brain in healthy individuals.
Furthermore, we wished to investigate whether a similar association exists in patients with a
psychotic disorder. To date, the validity of S100B as a proxy marker for white and grey matter
status has not been investigated in patients with psychotic disorder or other psychiatric mor-
bidity. We studied the potential association between serum S100B and neuroimaging markers
in patients with psychotic disorder, their non-psychotic siblings and controls. Our aim was to
assess S100B-associated alterations in brain structure in the context of increased risk (patients
and siblings) and disease-effects (patients) pertaining to psychotic disorder. In other words,
we tested whether a potential association between S100B and brain measures was moderated
by psychosis risk.
Although we previously reported an absence of association between S100B levels and (risk
of) psychotic disorder [1], we deemed it warranted to carry out further analyses for two main
reasons. First, the meta-analysis by Aleksovska and colleagues, which included our original
study, did find elevated S100B blood levels in schizophrenia [2]. Second, the absence of group
differences in S100B levels does not rule out an association between S100B and brain measures,
that may or may not be moderated by psychosis risk.
Materials and methods
Participants
Data was collected in the context of a longitudinal study in the Netherlands [7, 8], specifically
in Maastricht and surroundings (including representative parts of Belgium). Patients with a
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minimum age of 16 years with a diagnosis of non-affective psychosis were included. They were
recruited through the mental health services where they were treated, either as outpatients
(majority of the sample) or inpatients. Diagnosis was based on DSM-IV criteria (APA, 2000),
assessed with the Comprehensive Assessment of Symptoms and History (CASH) interview
[9]. Siblings were sampled through participating patients. Control subjects were recruited
from the same area as described above, using random mailings in nearby municipalities and
through advertisement in newspapers. The CASH was also used to confirm the absence of a
diagnosis of non-affective psychosis in the siblings, and absence of lifetime diagnosis of psy-
chotic disorder in the control subjects. For the control subjects, the occurrence of any psy-
chotic disorder in either the subject or any first-degree family member, assessed using the
Family Interview for Genetic Studies, constituted an exclusion criterion. Sufficient command
of the Dutch language was an additional criterion for inclusion.
Additional exclusion criteria constituted oncologic processes, autoimmune disease, current
infectious disease, cardiovascular disease and neurological disease; due to S100B elevation
associated with these types of pathology.
The cohort consisted of 32 patients with a psychotic disorder, 44 siblings and 26 controls.
Of note, the present study population is a subsample of the Maastricht cohort from our origi-
nal S100B study [1]. The subsample comprised all participants of whom both blood samples
and magnetic resonance imaging (MRI) scans were available. Therefore, this sample is a ran-
dom result of logistics, i.e. no specific selection was made from the original sample based on
demographic characteristics.
Of the patients, 21 were diagnosed with schizophrenia and 9 were diagnosed with schizoaf-
fective disorder. One patient was diagnosed with psychotic disorder not otherwise specified
(NOS) and one patient had a diagnosis of substance-induced psychotic disorder. As non-psy-
chotic psychiatric morbidity was not an exclusion criterion for siblings and controls, psychiat-
ric diagnoses were present in these groups. The sample thus included 17 siblings and 5
controls with a history of major depressive disorder (MDD).
A total of 14 families participated in the study. Nine families contributed one patient and
one sibling and one family contributed one patient and two siblings. Three families contrib-
uted two siblings, but no patients. One family contributed three siblings, but no patients.
Twenty-two independent patients, 24 independent siblings and 26 independent controls par-
ticipated, i.e. these individuals had no family ties within the sample.
Blood sample acquisition and processing
Blood serum samples were acquired by venipuncture and were centrifuged within 24 hours
and frozen until analysis. S100B was analyzed using a Liaison automated chemiluminescence
analyzer according to the manufacturer’s instructions (Diasorin). The lowest concentration of
detection was 0.02 microgram per liter. Receiver operator curves showed best accuracy for the
Liaison Sangtec 100 assay [10].
MRI acquisition and processing
MRI scans were obtained at Maastricht University, the Netherlands, using an Allegra syngo
MR A30 (Siemens, Erlangen, Germany) operating at 3.0 Tesla. The following anatomical scan
parameters were used: Modified Driven Equilibrium Fourier Transform (MDEFT) sequence;
176 slices, 1 mm isotropic voxel size, echo time 2.4 msec, repetition time 7.92 msec, inversion
time 910 msec, flip angle 15˚, total acquisition time 12 min 51 sec; Magnetization Prepared
Rapid Acquisition Gradient-Echo (MPRAGE; Alzheimer’s Disease Neuroimaging Initiative
(ADNI)) sequence 192 slices, 1 mm isotropic voxel size, echo time 2.6 msec, repetition time
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2250 msec, inversion time 900 msec, flip angle 9˚, total acquisition time 7 min 23 sec. The
matrix size was 256 x 256 and field of view was 256 x 256 mm2. The number of excitations was
one. Due to a scanner update during data collection nine participants (3 patients, 5 siblings
and one control) underwent the MDEFT sequence, while for the majority the ADNI sequence
was used.
Microstructural white matter anatomy was examined using diffusion tensor imaging (DTI)
with an echo-planar-imaging sequence (field of view 230 x 230 mm2, TR 10800 ms, TE 84 ms,
voxel size 1.8 x 1.8 x 1.8 mm3, b-value 1000 s/mm2, noise level 40, 85 slices, no overlap). As a
result of the scanner update, two DTI sequences were used: one with 76 directions (of which 4
T2-weighted (B0) and 72 diffusion-weighted (B)) and one with 81 directions (8xB0 and 73xB).
Only ten participants (3 patients, 6 siblings and 1 control) underwent the sequence with 76
directions. Total acquisition time of the DTI sequence was 15 minutes. Two male siblings did
not complete the DTI sequence and were excluded from the analysis.
Cortical thickness (CT) measurement
Scans were processed and analyzed using Freesurfer stable release v5.3.0, http://surfer.nmr.
mgh.harvard.edu [11–15]. To measure CT, the cerebral cortex was parcellated into units based
on gyral and sulcal structure [16, 17]. Furthermore, a variety of surface-based data was created
including maps of curvature and sulcal depth. This method used both intensity and continuity
information from the entire three dimensional MR volume in segmentation and deformation
procedures to produce representations of CT, calculated as the closest distance from the grey/
white matter boundary to the grey matter/cerebrospinal fluid (CSF) boundary at each vertex
on the tessellated surface [12]. The maps were created using spatial intensity gradients across
tissue classes and were not restricted to the voxel resolution of the original data, thus were
capable of detecting sub-millimeter differences between groups. CT measurement procedures
have been validated against histological analysis [18] and manual measurements [19, 20]. Indi-
vidual CT values for each predefined region of interest (hereafter: ROI; adapted from the Desi-
kan atlas [16], 34 ROIs per hemisphere) were derived by FreeSurfer and exported to R version
3.2.1. Thus, every individual had 68 CT measurements over the predefined ROIs.
Fractional anisotropy (FA) measurement
Processing of DTI data was effectuated using tract-based spatial statistics (TBSS) v1.2 in FSL
4.1.6 (FMRIB Analysis Group, Oxford, UK, http://www.fmrib.ox.ac.uk/analysis/research/
tbss). First, standard Siemens DICOM files were transformed into NIFTI format using a cus-
tom built in-house software package named GIANT (General Image ANalysis Tools developed
by EHBMG). Raw data were corrected for head movement and eddy currents invoked during
scanning. The B0 volume was skull-stripped using FSL’s Brain Extraction Tool [21] and this
served as a brain mask for all B volumes. The next step was fitting a diffusion tensor model at
each voxel using data output from the brain extraction, diffusion weighted data and gradient
directions following a general linear model (FreeSurfer v5.3.0). After tensor fitting the process
continued working on FA volumes, eroding them slightly.
Nonlinear registration aligned each FA volume to 1 x 1 x 1 mm standard FMRIB58_FA
space. The standard FMRIB58_FA contains a template derived from high-resolution images
of 58 participants in a well-aligned population (both males and females ranging between 20
and 50 years of age) [22]. After nonlinear transformation of the FA volumes into standard
space, a mean FA skeleton from all participants per group was derived. The mean FA skeleton
follows the major white matter tracts in each individual participant (normalized in MNI152
space) and provides a way to compare between (groups of) participants. The final step of the
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processing was setting the FA threshold using visual inspection of the FA skeleton, in the pres-
ent study at a level of 0.25, to include major white matter tracts whilst removing small periph-
eral tracts that would cause excess interparticipant variability. In addition, this threshold
setting avoided inclusion of regions that are likely to be composed of multiple tissue types or
fiber orientations.
The Johns Hopkins University International Consortium for Brain Mapping (JHU ICBM)-
DTI-81 white matter atlas labels [23] were used to assign specific tract names. From all 38 JHU
labeled white matter tracts, mean FA values were extracted and exported to R version 3.2.1.
Ethics statement
The study was approved by the standing ethics committee of Maastricht University Medical
Centre and all participants gave written informed consent in accordance with the committee’s
guidelines. When a participant was younger than 18 years of age, a parent co-signed the in-
formed consent form. Patients were outpatients, generally not in an acute illness stage. They
were approached directly, they made independent appointments in order to participate and
were supplied with ample verbal and written patient information before they provided in-
formed consent. Thus, in order to participate, their mental competence had to be evident both
by goal-directed behaviour enabling participation and from in-person contact when the study
was explained and informed consent was obtained. Furthermore, if a sibling was also a partici-
pant, patients were frequently accompanied by this sibling.
Statistical analyses
Conform previous work in this sample [7], datasets were transformed from a wide to long for-
mat resulting in a hierarchical structure, with 68 regional CT and 38 DTI measures (level 1)
nested in respectively 102 and 100 participants (level 2). Given the clustering of brain measures
within participants and participants within families, compromising statistical independence of
observations, multilevel random regression models were fitted [24]. R version 3.2.1 was used,
employing the nlme, car and multcomp packages. Since outcomes (CT and FA) represent
means (based on varying numbers of volumetric units, vertices and voxels respectively, per
region), the analyses were weighted based on the number of vertices/voxels per region.
Group × S100B interaction terms were evaluated using Wald-type tests [25]. A priori
planned stratified analyses per group were conducted. All analyses were adjusted for sex, age,
body mass index (BMI), scan sequence, handedness and highest level of education. In the
patient group, additional analyses were conducted correcting for current antipsychotic medi-
cation (AP) exposure by converting the daily dose to haloperidol equivalents (in milligrams).
In order to increase power, sensitivity analyses were conducted in healthy individuals (com-
bining controls and siblings) and individuals with (increased risk of) psychotic disorder (com-
bining siblings and patients).
Due to Streitbu¨rger’s sex-specific findings [6], S100B × sex and S100B × group × sex inter-
actions were evaluated in CT and FA models.
Results
Descriptive analyses
There was an uneven sex distribution in the patient group, with fewer females (28%) than
males. Controls were slightly older than siblings and patients, although not significantly so
(Table 1).
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Patients (P) had a higher mean BMI than controls (C) and siblings (S), the latter at trend-
level (P vs. C: B = 2.331, 95% CI 0.188 to 4.475, p = 0.033; P vs. S: 1.835, 95% CI -0.051 to
3.720, p = 0.056), whereas siblings and controls did not differ significantly (S vs. C: B = 0.497,
95% CI -1.511 to 2.505, p = 0.625).
Twenty-seven out of 32 patients reported current use of antipsychotic (AP) medication.
Nine patients used risperidone, four used olanzapine, three used aripiprazole, two used cloza-
pine, two quetiapine and two used amisulpride. There was a single case of bromperidol use.
One person used a combination of risperidone and paliperidone, one used clozapine and aripi-
prazole, one person used aripiprazole and olanzapine, and one person used haloperidol and
pipamperone.
Mean S100B, CT and FA
Mean S100B levels appeared lower in patients than in controls and siblings, with siblings hav-
ing the highest values (see Table 1). Regression analyses corrected for potential confounders
(sex, age and BMI) showed that there was no significant difference in S100B serum levels
between patients and controls (P vs. C: B = -0.013, 95% CI -0.033 to 0.007, p = 0.208), in line
with our first S100B study [1]. However, patients did have lower S100B levels than siblings
(P vs. S: B = -0.019, 95% CI -0.036 to -0.002, p = 0.031). There was no significant difference
between S100B in siblings and controls (B = 0.006, 95% CI -0.012 to 0.024, p = 0.529).
Mean CT was significantly lower in patients than in controls and siblings (at trend level)
when corrected for sex, age, BMI, scan sequence, handedness and highest level of completed
education, and weighted for number of vertices (P vs. C: B = -0.049, 95% CI -0.095 to -0.003,
p = 0.037; P vs. S: B = -0.036, 95% CI -0.073 to 0.002, p = 0.065), with no significant difference
between siblings and controls (B = -0.013, 95% CI -0.054 to 0.027, p = 0.521).
Mean FA was significantly lower in patients and siblings compared to controls, with no
significant difference between patients and siblings; again controlled for sex, age, BMI, scan
sequence, handedness and highest level of completed education, and weighted for number
of voxels (P vs. C: B = -0.016, 95% CI -0.025 to -0.007, p = 0.001; S vs. C: B = -0.013, 95% CI
-0.021 to -0.004, p = 0.004; P vs. S: B = -0.003, 95% CI -0.010 to 0.003, p = 0.308).
Associations between S100B and brain structure
No significant associations between S100B and CT (B = 0.311, 95% CI -0.116 to 0.739,
p = 0.154) and S100B and FA (B = 0.030, 95% CI -0.055 to 0.116, p = 0.485) were observed in
the total sample.
Table 1. Demographic characteristics.
Controls Siblings Patients
Number of participants 26 44 32
Sex (male/female) 11/15 24/20 25/7
S100B (μg/l) 0.083 ± 0.031 0.087 ± 0.044 0.067 ± 0.029
CT 2.539 ± 0.399 2.546 ± 0.397 2.496 ± 0.395
FA 0.588 ± 0.081 0.575 ± 0.082 0.572 ± 0.085
Age 33.77 ± 11.16 30.39 ± 7.96 30.78 ± 6.49
BMI 23.65 ± 3.36 24.15 ± 4.38 25.99 ± 4.21
Present use of AP (yes/no) 27/5
Haloperidol equivalents (mg) 4.38 ± 3.37
Means ± standard deviations reported.
https://doi.org/10.1371/journal.pone.0174752.t001
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Interactions
Neither the group × S100B in the CT model (χ2 = 0.044, p = 0.978), nor the group × S100B
interaction in the FA model (χ2 = 3.672, p = 0.159) were significant, confirmed by stratified
analyses (Table 2).
S100B × sex and S100B × group × sex interactions in the CT model were not significant
(χ2 = 0.135, p = 0.713; and χ2 = 2.130, p = 0.345, respectively), nor were those in the FA model
(χ2 = 0.025, p = 0.874; and χ2 = 0.194, p = 0.907, respectively).
Sensitivity analyses
Combining controls and siblings into one “healthy” group (n = 70) showed no associations
between S100B and brain measures (CT: B = 0.274, 95% CI -0.130 to 0.678, p = 0.184; FA: B =
-0.053, 95% CI -0.158 to 0.053, p = 0.331). Nor did the combination of siblings and patients
into an (at risk of) psychosis group (n = 76) result in significant findings (CT: B = 0.332, 95%
CI -0.152 to 0.817, p = 0.179; FA: B = 0.063, 95% CI -0.020 to 0.146, p = 0.136).
Correcting for current AP exposure in the patient group resulted in non-significant associa-
tions in both (grey and white matter) models (CT: B = 0.141, 95% CI -0.960 to 1.241, p =
0.802; FA: B = 0.129, 95% CI -0.086 to 0.345, p = 0.240).
Discussion
We investigated the potential relationship between serum S100B and structural cerebral mea-
sures in both healthy subjects (in replication of previous work) and individuals with (increased
risk of) psychotic disorder (not examined previously). No significant associations between
serum S100B and cerebral structural measures were found in health or in the presence of
(increased risk of) psychotic disorder.
Findings
Our first S100B study showed no association between (risk of) psychotic disorder and S100B
[1]. We now report no association between S100B and brain structure in the presence of
(increased risk of) psychotic disorder in the same sample. Unfortunately these results cannot
be surveyed in the broader context of schizophrenia research as there are no analogous studies
(yet) to compare it with.
Furthermore, we do not find that CT and FA are consistently associated with S100B in con-
trols and healthy siblings. The only previous study to explore the association between S100B
and brain structure using neuroimaging was performed in healthy controls [6]. This study sug-
gested S100B-related demyelination in women (negative correlation with FA and a positive cor-
relation with radial diffusivity). The analyses conducted by Streitbu¨rger and colleagues were a
priori stratified per sex, although they proceed to conclude that true sex-related differential
expression patterns of S100B in the brain were not anticipated. The present study explored
whether S100B effects on CT and FA were conditional on sex (S100B × sex interaction) and
Table 2. Associations between S100B and cerebral structural measures.
Controls Siblings Patients
B (p-value) B (p-value) B (p-value)
Cortical thickness 0.264 (0.603) 0.287 (0.310) 0.171 (0.720)
Fractional anisotropy -0.135 (0.216) 0.021 (0.702) 0.120 (0.110)
B’s and p-values reported. B represents the regression coefficient of the multilevel regression analyses.
https://doi.org/10.1371/journal.pone.0174752.t002
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group and sex (S100B × group × sex interaction). No significant interactions were found.
Indeed, our original study did not show significant group × sex interactions in two large inde-
pendent samples [1]. So although sex-specific patterns in neuroimaging studies are well docu-
mented, this appears unrelated to levels of S100B in the present study. However, bearing in
mind that the sample size is modest the three way interaction likely lacks power.
We did not find any significant associations between S100B and grey matter status repre-
sented by cortical thickness in any of the 3 groups. This is in line with Streitbu¨rger’s finding of
absence of association between S100B and grey matter density [6] in healthy controls.
Due to the absence of association between serum S100B and brain structure in the
current study’s patient group (also after correction for current AP use), we are unable to
make any deductions about S100B’s cerebral actions in schizophrenia. S100B has dual
effects: at physiological intracellular levels and nanomolar extracellular concentrations it is
neurotrophic [26]; at micromolar levels it becomes neurotoxic [26–28]. As Streitbu¨rger [6]
and Schmitt [29] have pointed out, S100B elevation in schizophrenia is within the nanomo-
lar range. That is to say that the micromolar S100B concentrations seen in clear neuronal
damage (e.g. after traumatic brain injury or infarction) do not seem applicable to schizo-
phrenia. S100B elevation in the nanomolar range is compatible with neurotrophic action.
This makes a neurodegenerative process improbable and regenerative action more likely
[6, 29].
The interpretation of our results may be complicated by the fact that mean S100B was low-
est in patients, significantly so compared to siblings. Noteworthy is the fact that mean S100B
was highest in the patient groups in the original study [1], although there were no significant
differences in S100B levels between groups in the analyses. As the present sample (a subsample
from the original study) is a result of logistics and not of specific selection criteria, we have no
explanation for the low S100B levels in the present patient group and therefore conclude that
these likely represent chance. Nevertheless, this potentially indicates an issue with power
which may result in false negative findings.
Methodological considerations
There are several limitations in the present study that deserve discussion.
First, scanner updates took place at an early stage during the data collection period. This led
to an uneven distribution of scan types (within and between groups). The majority of partici-
pants underwent the ADNI sequence and DTI acquisition with 81 directions, though 9
MDEFT sequence scans and 10 DTI scans with 76 directions were obtained. To account for
potential confounding by uneven distribution over the groups, scan type was included as a
covariate in all analyses. As an extra test, we repeated analyses excluding the MDEFT sequence
and the DTI scans with 76 directions. This did not alter the associations between S100B and
CT and FA respectively (results not shown).
Second, there were 17 siblings and 5 controls with a history of MDD in this study sample.
The findings from our original study indicated that there were no differences in serum S100B
between these groups and that the inclusion of MDD and other psychiatric comorbidity in
these groups did not alter the pattern of negative findings. As the original study [1] consisted
of two independent samples of ample size (allowing for independent replication of our find-
ings) we presume that the findings in controls and siblings were not influenced by MDD. We
also base the combination of controls and siblings into a “healthy” group on the premise of
absence of associations between S100B and group in the original study.
Third, the patient group was clinically heterogeneous, i.e. inclusion criteria were broader
than a diagnosis of schizophrenia. As an extra test, we excluded patients with a diagnosis other
Serum S100B: A proxy marker for grey and white matter status in the absence and presence of
(increased risk of) psychotic disorder?
PLOS ONE | https://doi.org/10.1371/journal.pone.0174752 March 30, 2017 8 / 11
than schizophrenia and repeated all analyses (results available upon request). The pattern of
findings was not significantly altered.
And finally, mean CT and FA are coarse measures of brain structure. Taking this into con-
sideration, in combination with small sample size, the present study may best be considered as
hypothesis-generating.
As this is the first study to investigate an association between S100B and cerebral structural
measures in psychotic disorder, no comparison can be made to previous work. Naturally, rep-
lication of our study in a larger cohort is required to either corroborate or refute findings.
Conclusions
No evidence was present for S100B as a proxy marker of grey or white matter status. The asso-
ciation between S100B and brain measures was not moderated by psychosis risk.
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